Keyphrases
Lymphoma
46%
National Cohort Study
44%
Lymphoma Patients
34%
Danish Population
34%
Confidence Interval
31%
Classical Hodgkin Lymphoma
23%
Population-based Cohort Study
22%
Background Population
21%
Anthracyclines
21%
Overall Survival
19%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Congestive Heart Failure
17%
Population-based Study
15%
Bleomycin
15%
R-CHOP
13%
Cumulative Risk
12%
Hodgkin Lymphoma
12%
Denmark
12%
Acute Myeloid Leukemia
11%
Hazard Ratio
11%
Second Primary Malignancy
10%
Osteoporosis
10%
Treatment Outcome
10%
Cardiotoxicity
10%
Return to Work
10%
Treatment Strategy
10%
Population-based Retrospective Cohort Study
10%
Elderly Survivors
10%
Autologous Hematopoietic Stem Cell Transplantation
10%
Bendamustine
10%
Bone Mineral Density
10%
Work Disability
10%
Indolent Lymphoma
10%
High-dose Chemotherapy
10%
BTK Inhibitor
10%
Pulmonary Disease
10%
Matched Cohort Study
10%
Myeloid Malignancies
10%
Second Primary
10%
Adult Acute Lymphoblastic Leukemia
10%
Intensive Care Medicine
10%
Non-Western Immigrants
10%
Migrant Patients
10%
Leukemia Survivors
9%
Disability Pension
9%
Bruton Tyrosine Kinase Inhibitor
8%
Adriamycin
8%
Follicular Lymphoma
8%
High Risk
8%
Prednisone
8%
Medicine and Dentistry
Cohort Analysis
100%
Diffuse Large B-Cell Lymphoma
38%
Doxorubicin
31%
Classical Hodgkin Lymphoma
28%
Cardiovascular Disease
24%
Hazard Ratio
23%
Acute Myeloid Leukemia
22%
High Dose Chemotherapy
21%
Immigrant
21%
Overall Survival
20%
Congestive Heart Failure
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Hodgkin's Lymphoma
14%
Anthracycline
14%
Bleomycin
11%
Second Cancer
10%
Osteoporosis
10%
Work Disability
10%
Health Care
10%
Cardiovascular Disease in Elderly
10%
Diabetes
10%
Retrospective Cohort Study
10%
Diabetes Mellitus
10%
Disability Pension
10%
Stem Cell Transplant
10%
Positron Emission Tomography-Computed Tomography
10%
Autologous Hematopoietic Stem Cell Transplantation
10%
Silo-Filler's Disease
10%
Hematological Cancer
10%
Myeloid Malignancy
10%
Population
9%
Bruton Tyrosine Kinase Inhibitor
8%
Drug Megadose
8%
Cumulative Incidence
7%
Atmospheric Aerosols
7%
Elderly Patient
6%
Mantle Cell Lymphoma International Prognostic Index
6%
Prednisolone
6%
Diseases
5%
Clinical Trial
5%
Charlson Comorbidity Index
5%
Follicular Lymphoma
5%
Patient Registry
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
57%
Anthracycline
23%
Overall Survival
23%
Congestive Heart Failure
23%
Diffuse Large B Cell Lymphoma
22%
High Dose Chemotherapy
21%
Cardiovascular Disease
21%
Doxorubicin
21%
Classical Hodgkin Lymphoma
19%
Follicular Lymphoma
13%
Cardiotoxicity
12%
Disease
12%
Malignant Neoplasm
11%
Bendamustine
10%
Second Cancer
10%
Patient Registry
10%
Alendronic Acid
10%
Mantle Cell Lymphoma
10%
Prednisolone
10%
Hodgkin Disease
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Bruton Tyrosine Kinase Inhibitor
8%
Chemotherapy
7%
Glucocorticoid
7%
Placebo
5%
Bleomycin
5%
